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PQUARTERLY FOCUS ISSUE: HEART FAILURE
Ventricular Assist Devices
The Challenges of Outpatient Management
Sean R. Wilson, MD,* Michael M. Givertz, MD,† Garrick C. Stewart, MD,†
Gilbert H. Mudge, JR, MD†
New York, New York; and Boston, Massachusetts
The need for mechanical assistance of the failing heart, whether acute after a myocardial infarction or perma-
nent in patients with end-stage heart failure, has increased with improvements in medical therapy and a grow-
ing aged population. Over the past few decades, much progress has been made in the development and refine-
ment of ventricular assist devices (VADs), medical devices capable of maintaining circulatory output of the
diseased ventricle. Initially designed as a temporary support to allow ventricular recovery or as a bridge for pa-
tients to cardiac transplantation, these devices are now being used as a permanent form of “destination” ther-
apy. Improvements in technological design, durability, and medical management have allowed individuals with
VADs to be managed in their communities. Although these devices provide excellent hemodynamic support and
enhance patient functional status, discharged individuals face many unique challenges. In this article, we dis-
cuss 1) the spectrum of VADs for outpatient therapy, including their basic physiology and hemodynamics; 2) the
multidisciplinary approach required to care for a patient with such a device in the community; 3) routine general
cardiac issues that are encountered; 4) associated long-term device and nondevice-related complications; and 5)
the reported overall improvements in quality of life. (J Am Coll Cardiol 2009;54:1647–59) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.035m
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Cespite widespread use of evidence-based therapies to
educe the morbidity and mortality of heart failure, the
ncidence of heart failure has not changed, and it remains
he most common hospital discharge diagnosis for patients
lder than 65 years of age (1–5). Heart failure is a progres-
ive disease, and individuals at the end of life have few
ptions, given the limitations of intravenous positive ino-
ropes and a finite number of donor organs (6). Multiple
ifferent mechanical devices for long-term circulatory sup-
ort have been developed, ranging from total artificial hearts
o ventricular assist devices (VADs). The main purpose of a
AD is to unload the failing heart and help maintain
orward cardiac output and vital organ perfusion. Originally
ntroduced as a temporary bridge to recovery and then as a
ridge to transplantation, VADs have evolved into perma-
ent or “destination” therapy for a growing number of
atients with refractory heart failure (7). After VAD place-
ent, many patients are discharged to their home commu-
ities. Once outpatients, individuals with an implanted
AD, whether indicated as a bridge to recovery or trans-
lantation or as destination therapy, face similar lifestyle
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edical College, New York, New York; and the †Cardiovascular Division, Brigham
nd Women’s Hospital, Harvard Medical School, Boston, Massachusetts.s
Manuscript received February 24, 2009; revised manuscript received June 18, 2009,
ccepted June 21, 2009.odifications and long-term management issues. Although
hese patients will always require the attention of specialized
eart failure centers, they also rely on the support of their
ommunity medical care providers. This review describes
he current state of VAD technology and the challenges of
aring for patients with a VAD living outside the hospital.
verview of VADs
ndications for device therapy. Mechanical devices may
e considered for a wide spectrum of diseases based on the
nticipated duration and therapeutic goals of circulatory
upport. The classification is typically broken down into 3
ategories: bridge to recovery, bridge to transplantation, and
estination therapy. Bridge to recovery is reserved for
atients who need only temporary support for days to weeks
uring which time reversibility of ventricular insult may
ccur followed by weaning and removal of device. This
ncludes patients with acute cardiogenic or post-cardiotomy
hock, acute inflammatory cardiomyopathies, and myocar-
ial infarction. The second cohort is bridge to transplanta-
ion. These patients meet the criteria but need additional
irculatory support while awaiting transplantation. Destina-
ion therapy categorization is reserved for patients who are
ot candidates for transplantation yet require the use of a
AD as a final therapy until death.
omponents of a VAD. VADs used in the outpatientetting are implanted devices placed through a median
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Ventricular Assist Devices: Outpatient Management October 27, 2009:1647–59sternotomy typically during car-
diopulmonary bypass. The VAD
is connected to the heart by an
inflow cannula that decom-
presses the ventricular cavity and
an outflow cannula that returns
blood to either the ascending
aorta or the main pulmonary ar-
tery. The pumping chamber of
the VAD is implanted subdia-
phragmatically to a pre-peritoneal
or intra-abdominal position or
may be situated in a paracorpo-
eal position outside the body. Smaller devices are being
eveloped for thoracic implantation, some with outflow to
he descending aorta. A percutaneous driveline, containing
he control and power wires, is tunneled through the skin
f the abdominal wall. It connects the device to an external
ortable driver consisting of an electronic or pneumatic
ontroller and a power supply that may be worn around the
aist, carried in a shoulder bag, or contained within a small
edside monitor (Fig. 1).
hysiology of VADs. RIGHT OR LEFT VENTRICULAR
UPPORT. VADs support the failing heart by unloading the
entricle and generating flow to the systemic and/or pul-
onary circulation. This creates parallel pumping chambers
hat compete for the same venous return (pre-load) and face
he arterial resistance (afterload) of their respective pulmo-
ary and systemic vascular beds. Under optimal conditions,
he native ventricle is a passive conduit through which the
Abbreviations
and Acronyms
ICD  implantable
cardioverter-defibrillator
LVAD  left ventricular
assist device
QOL  quality of life
RVAD  right ventricular
assist device
VAD  ventricular assist
device
Figure 1 Components of a Continuous Flow VAD
A continuous flow ventricular assist device (VAD) consists of a pump connected to
external driveline that powers the motor within the device, and a system controller
increased mobility. Figure illustration by Rob Flewell. LVAD  left ventricular assisechanical pump fills throughout the cardiac cycle, and the
ecompressed ventricle should contribute little to the sys-
emic cardiac output. If a ventricular stroke volume is
enerated and the aortic/pulmonic valve leaflets are seen to
pen on echocardiography, either return of native ventric-
lar function or inadequate decompression of the native
entricle and device dysfunction should be suspected.
Isolated right ventricular dysfunction requiring insertion
f a right ventricular assist device (RVAD) to support the
ailing ventricle is a rare event. Cases have been reported
ost-cardiotomy after an acute myocardial infarction, coro-
ary artery bypass grafting, and valvular surgery. More
ommonly, an RVAD may be inserted around the time of
lacement of a left ventricular assist device (LVAD) to
rovide biventricular assistance.
IVENTRICULAR SUPPORT. The unique physiology created
y a mechanical pump is further complicated if biven-
ricular support is need. Unlike a single VAD, biventricu-
ar mechanical devices create a complex system with 2
ndependent pumps, one right sided and the other left
ided. Left atrial venous return is normally greater than
ight atrial pre-load because of the bronchial circulation,
o overall left-sided output (LVAD plus native left
entricle) must always be greater than right-sided output
RVAD plus native right ventricle) or else pulmonary
dema may develop. In addition to navigating complex
iventricular cannula insertion anatomy, native right and
eft ventricular function may also recover at different
ates.
eart and aorta via an inflow cannula and an outflow cannula, respectively, an
r may be delivered through a power base unit (PBU) or battery packs, allowing
e.the h
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October 27, 2009:1647–59 Ventricular Assist Devices: Outpatient Managementevice type. These devices can be broadly categorized as
ither displacement pulsatile or rotary continuous flow
umps (Table 1).
ULSATILE PUMPS. Pulsatile or displacement pumps have
een the most commonly used devices in the U.S. These
umps consist of inflow and outflow conduits, unidirec-
ional valves, a pumping chamber, a battery pack, and a
ystem controller and may be driven pneumatically or
lectrically (Fig. 2). Pneumatic pumps, such as Thoratec’s
aracorporeal Ventricular Assist Device and Implantable
entricular Assist Device (Thoratec Corporation, Pleasan-
on, California) send a predetermined air pressure through
ubing to fill a sac cyclically, which displaces a stroke
olume. In contrast, the pulsatile HeartMate XVE (Thor-
tec Corporation) uses an electromagnetic pusher plate to
rive blood flow.
echanical Cardiac Support DevicesTable 1 Mechanical Cardiac Support Devices
Volume-Displacement Pumps
(First-Generation Devices)
Method of displacement Pulsatile chamber or sac that fills passively or by suctio
and is compressed by external pusher plate
Blood pressure Cyclic, pulsatile flow
Valve Inflow and outflow prosthetic valves
Devices implanted during
cardiac surgery
HeartMate XVE, Novacor, Thoratec PVAD or IVAD,
Abiomed 5000, LionHeart*
Investigational (not approved by the U.S. Food and Drug Administration) devices.
HVAD  HeartWare ventricular assist device; IVAD  implantable ventricular assist device; LVA
Figure 2 Components of a Pulsatile VAD
A pulsatile VAD consists of a pump, battery pack, and controller. An LVAD
decompresses the ventricle into a pump that directs blood into the aorta. The
inflow cannula is surgically implanted into the ventricular apex and the outflow
cannula is inserted into the ascending aorta. Figure illustration by Rob Flewell.
Abbreviations as in Figure 1.vWith each ejection, the pulsatile pumps impart a stroke
olume, producing a pulse pressure that mimics systole and
iastole of the native heart. Pulsatile devices are typically not
hased to the contractions of the heart but can capture the
ntire cardiac output and are often operated with a fixed
troke volume and variable beat rate. Despite the improve-
ents in cardiac function and systemic blood flow seen with
ulsatile VADs, their adoption has been constrained by
heir size and weight and the need for extensive surgical
issection at the time of implantation.
ONTINUOUS FLOW PUMPS. Continuous flow rotary pumps
ave become increasingly available, and many are now
he subject of ongoing clinical investigations, including the
horatec HeartMate II Left Ventricular Assist System, the
icroMed DeBakey Ventricular Assist Device (Micromed
icrovascular Inc., Houston, Texas), and the Jarvik 2000
eart (Jarvik Inc., New York, New York) (8–11). This
echnology accelerates blood through only 1 bearingless
entral rotor powered by a miniaturized motor (Fig. 1).
hese pumps are driven by either a spinning impeller (axial
ow pumps) forcing blood along the axis of the rotor or
oncentric cones (centrifugal pumps) accelerating the blood
ircumferentially.
The generation of continuous blood flow in a nonphysi-
logic manner eliminates the need for valves or compliance
hambers. To mimic physiologic flow, continuous flow
ADs have a mode of operation (pulsatility index) that
ermits aortic valve opening during systole by adjusting the
otations per minute of the device. The pulsatility index
range 1 to 10) is representative of the magnitude of flow
ulse generated by the pump through each cardiac cycle.
he pulsatility index represents the balance of native ven-
ricular function and unloading by the continuous flow
AD. The pulsatility index is routinely monitored and
djusted to ensure safe automatic flow control and may be a
seful piece of information when assessing a change in
linical status. Potential advantages of axial flow pumps
nclude smaller size, easier surgical implantation, quieter
ibration-free operation, enhanced patient comfort, and
xtended durability (11). Much is being learned about the
hysiologic and pathologic effects of continuous flow de-
Rotary Blood Pumps (Second-Generation Devices)
Axial Flow Pumps Centrifugal Flow Pumps
ntinuous flow driven by a spinning
rotor around a central shaft
Continuous flow driven by a hydrodynamic or
electromagnetic suspended spinning rotor
nstant, nonpulsatile flow Constant, nonpulsatile flow
valves No valves
artMate II, Jarvik 2000,*
MicroMed DeBakey,* Incor*
VentrAssist,* HVAD,* Terumo Dura Heart,*
HeartWare,* HeartQuest,* MTIHeart
LVAD*
t ventricular assist device; PVAD  paracorporeal ventricular assist device.n Co
Co
No
Heices for cardiac support. Initially, many questions and
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Ventricular Assist Devices: Outpatient Management October 27, 2009:1647–59oncerns were raised regarding the impact of a continuous
ow device on the systemic circulation and post-
ransplantation outcomes (12,13). Recently published liter-
ture suggests that continuous compared with pulsatile
ADs provide favorable hemodynamic circulatory assis-
ance to support end-organ function and functional status
11,14,15).
rogrammable functions of VADs. VADs have program-
able functions including mode of operation, device rate,
rive pressure, vacuum pressure, and duration of systole for
he pneumatic pump, along with rotary speed for continu-
us flow pumps (Table 2).
pproved VADs. Multiple VADs are approved by the
.S. Food and Drug Administration for bridge to trans-
lantation or recovery. These include the pulsatile Thoratec
aracorporeal VAD and the implantable LVAD and
VAD, Novacor LVAD (Novacor, Rueil-Malmaison,
rance), HeartMate XVE LVAD (Thoratec Corporation),
arvik 2000 (Jarvik Inc.), and HeartMate II LVAD (Thoratec
orporation) (Fig. 3, Table 3). The only device currently
pproved for destination therapy is the HeartMate XVE
VAD. The HeartMate II is an axial flow pump recently
pproved for bridge to transplantation, and it and the Jarvik
000 are under investigation for destination therapy. Each
f these devices may be encountered in the outpatient
etting. Additionally, there are many ongoing clinical trials
xamining the next generation of VADs along with potential
trategies to improve the long-term outcomes of these patients
Table 4).
hanges in Ventricular
unction After Implantation
istologic and biochemical signs of recovery. Although
he major purpose of a VAD is to assume the pumping
unction of the heart, the reduction in myocardial stretch
fter VAD decompression may lead to a recovery process
eferred to as reverse ventricular remodeling (16). Improve-
ent in intrinsic myocyte function may occur because of
lterations in abnormal gene expression, changes in collagen
ontent, regression of cellular hypertrophy, and reduction in
yocytolysis and inflammatory cytokines (17–20). Al-
hough such changes may occur, most patients do not fully
ecover and are ineligible for explantation (21).
odes of VAD OperationTable 2 Modes of VAD Operation
Modes of Operation Timing of
Volume displacement
pumps
Asynchronous Rate of VAD is fixed and asynch
Volume or automatic* Asynchronous from native QRS
passively according to the lef
External synchronous* Synchronized to native QRS com
Rotary blood pumps Fixed rate Constant pump speed (rotations
Variable rate Speed of pump adjusts to the a
cardiac contractilityA backup device rate is needed when placing patients in either volume or external asynchronous mode
VAD  ventricular assist device.linical approach to encourage myocardial recovery. The
ate of clinical recovery leading to device explantation is low
nd dependent on the wide heterogeneity and severity of
edical conditions for which VAD support is used. To help
romote reverse remodeling, efforts are under way to assess
he use of disease-altering pharmacologic regimens in VAD
atients. It is hoped that such therapies in conjunction with
entricular decompression by VAD support will act as a
ridge to recovery. At the present time, all patients who
ppear to be bridge to recovery candidates are restarted on
eurohormonal antagonists, which are then up-titrated to
ublished guidelines as tolerated. It is not yet understood
hich heart failure patients are the best candidates for the
nstitution of additional aggressive adjunctive therapies.
ctive clinical research to help determine who would
enefit from such strategies is ongoing.
In 2006, Birks et al. (22) reported the successful reversal
f remodeling in selected VAD patients with nonischemic
ardiomyopathy treated with clenbuterol, a selective 2-
gonist. The researchers devised a 2-stage pharmacologic
anagement approach after implantation, along with diag-
ostic functional and echocardiographic criteria for weaning
atients from VAD support (Table 5). Building on these
romising data, the Harefield Recovery Protocol Study has
egun to enroll LVAD patients with a history of chronic
efractory heart failure. This study is examining whether
djunctive clenbuterol treatment leads to sufficient improve-
ent in myocardial function to allow device removal. There
s hope that further combinations of mechanical unloading
nd drug therapy may enhance myocardial recovery and
llow device explantation.
reparing for Life Outside of the Hospital
he ultimate success of a VAD depends on appropriate
reparation of patients and their caregivers for the return
ome from the hospital. Proper training of both the patient
nd the community allows for a smooth transition to life
utside the hospital, increasing patient satisfaction and
uality of life (QOL) (23).
raining for discharge. PSYCHOLOGICAL RECOVERY AND
REPARATION OF PATIENT AND FAMILY. VAD patients
ace a unique set of challenges and stressors: loss of work
rt Indication(s) for Use
to native QRS complex Initiation of mechanical support, weaning from device,
and during times of hemodynamic instability
ex, pumping is adjusted
icular filling volume
Outpatient routine operation, exercise
Weaning from device
Initiation of mechanical support, weaning from device
level of patient and Outpatient routine operation, exerciseSuppo
ronous
compl
t ventr
plex
/min)
ctivitys of support. Backup rates are typically pre-set at 50 to 60 beats/min.
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October 27, 2009:1647–59 Ventricular Assist Devices: Outpatient Managementnd independence, concern with burdening caregivers, fear
f complexity in managing the device or related equipment,
hange in family dynamics, strain on finances, and fear of
ying. Patients must be screened for emotional and psycho-
ogical readiness, family and social support, and home safety
24,25). Before discharge, a VAD patient and his or her
aregivers must be comfortable and competent to assume
esponsibility for daily monitoring, device maintenance, and
ndependent performance of activities of daily living. The
ome environment is assessed, and family and friends are
ducated about the major system components and how to
dentify and respond appropriately to alarm symbols and
Figure 3 Schematics of Commonly Used VADs
Mechanical support systems: Thoratec VAD (top left), Novacor LVAD (top right), H
depicting the mechanisms of action of an axial flow and volume displacement pum
a small device consisting of a continuously spinning impeller along a central shaft
with minimal hemolysis. The pulsatile pump of the HeartMate XVE uses an electro
plate can provide between 5 and 10 l/min of pulsatile blood flow. Figure illustratioudible tones. sEHABILITATION. Adequate cardiac rehabilitation in-
luding physical, occupational, and nutritional therapy is
central part of the patient’s recovery from VAD
mplantation. Although this is often achieved during
ospitalization after surgery, long-term rehabilitation
eeds may persist for some patients who have not
emonstrated satisfactory self-care and ability to live
ndependently. Unfortunately, this may be impossible to
rrange in a typical community setting. Most rehabilita-
ion facilities are unwilling to take VAD patients due to
lack of training or knowledge about the technology,
lthough in our experience this can be overcome with a
ate II LVAD (bottom left), and HeartMate XVE LVAD (bottom right). Illustrations
shown for the HeartMate II and HeartMate XVE devices. The axial flow pump is
is drawn from the spinning blades of the impeller and propelled at 4 to 6 l/min
tic pusher plate to cyclically expand and decompress a chamber. The pusher
ob Flewell. Abbreviations as in Figure 1.eartM
ps are
. Blood
magne
n by Rtrong collaborative relationship.
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Ventricular Assist Devices: Outpatient Management October 27, 2009:1647–59hysical exercise. Once discharged, it is highly recom-
ended that patients continue to improve their physical
erformance. If deconditioned, patients should be sent to an
utpatient cardiac rehabilitation program to help them work
n gaining strength and improving their endurance and
nergy capacity. Compared with ambulatory patients with
evere heart failure, VAD patients have improved rest and
xercise hemodynamics, as demonstrated by an increase in
eak oxygen consumption (V˙O2), decrease in peak minute
entilation/carbon dioxide production (V˙E/V˙CO2), increase
n cardiac output, and reduction in mean pulmonary artery
nd wedge pressures (15,26). These improvements in max-
mal exercise capacity suggest that the VAD’s ability to
nload the ventricle leading to profound ventricular pressure
nd volume changes leads to reversal of neurohormonal
ctivation, impaired metabolic vasodilation, and myocardial
emodeling (27,28).
utrition. The nutritional status of a VAD patient should
e checked periodically. Patients who have malnutrition,
articularly cachexia or hypoalbuminemia, may be predis-
osed to immune system dysfunction, impaired healing, and
nfection (29,30). Assessment by a nutritionist may be
ecessary along with appropriate supplementation. Changes
n inflammation can be used to monitor the metabolic
esponse to nutritional support by measuring plasma levels
f C-reactive protein and prealbumin. If the C-reactive
rotein increases or the negative acute-phase reactive pre-
lbumin decreases, more nutritional support may be neces-
ary. Other parameters including low lymphocyte count and
otal cholesterol can be of assistance to ensure optimal
ecovery (31).
outine self-care. Once discharged home, patients and
amily members are required to perform periodic cleaning
nd maintenance of VAD equipment. This includes chang-
ng the dressing at the exit site, inspecting for signs of
nfection, measuring daily vital signs, examining the con-
ectors and ventilator filter for dirt or debris, and assessing
he status of the batteries. Patients are permitted to shower
nly after the surgery site has healed completely. Because
AD components are not waterproof, it is critical to keep
he vent filter, system controller, and batteries dry. Specially
esigned covers made from wetsuit material are used to
omparison of Current VAD Technology for Outpatient CareTable 3 Comparison of Current VAD Technology for Outpatient
HeartMate XVE WorldHeart No
Position Internal Internal
Patient size Large Large
Power Electric Electric
Capability LVAD LVAD
Duration Yrs Yrs
Recommended anticoagulation
Antiplatelet therapy Yes No
Warfarin therapy No Yes
IVAD  biventricular assist device; LVAD  left ventricular assist device; RVAD  right ventricularotect the conduits, providing independence and allowing aatients to feel comfortable around water. Swimming or
aking a bath is not permitted, and water in the device may
ause the pump to stop.
armful environments. As outpatients, VAD patients
ay resume many of their previous normal activities, but
here are some restrictions that must be maintained to
nsure their well-being and optimal device function. Due to
he sensitive nature of these machines, patients should avoid
xtremes of temperature for prolonged periods of time.
ecause VAD patients remain permanent susceptible hosts
o infection, they should be cautious in surroundings that
an place them at a greater risk (e.g., day care facilities,
ontact with sick individuals, crowded living conditions,
oor hygiene). Patients should avoid operating heavy ma-
hinery and must not engage in contact sports or strenuous
ctivities. Serious injury may occur if patients undergo a
agnetic resonance imaging study. Additionally, it is rec-
mmended that individuals avoid power stations and power
ines for possible electrical interference.
esponsibility of primary care physicians and nurse
ssociations. Primary health care providers play an impor-
ant role in successful outpatient management and should be
roperly instructed in the basic management of VADs. Such
roviders should be aware of the potential for infection and
eurologic complications, as well as pump stoppage, but
hould not be asked to assume primary responsibility for
ong-term VAD care or fully understand the nuances of
evice technology. A visiting nurse association will be
niformly asked to provide home support for all VAD
atients. Meticulous attention must be paid to wound care
o avoid driveline infections, and, in addition, there are
requent blood draws for laboratory tests, medication ad-
ustments, and routine contact with the VAD team.
ole of first responders. Local first responders and emer-
ency department personnel should become familiar with the
asic physiology, system operation, and components of a
AD. Many VAD programs have established outreach pro-
rams that teach first responders basic issues concerning
roubleshooting and pump stoppage (32–34). When an emer-
ency does occur, emergency medical services should bring all
omponents of the device (e.g., hand pumps, extra batteries,
Thoratec VAD System HeartMate II Jarvik 2000
Internal or external Internal Internal
Small to large Small to large Small
Pneumatic Electric Electric
LVAD, RVAD, or BIVAD LVAD LVAD
Possibly yrs Yrs Possibly yrs
No Yes No
Yes Yes Yes
t device; VAD  ventricular assist device.Care
vacornd primary and backup drivers) to the local emergency
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October 27, 2009:1647–59 Ventricular Assist Devices: Outpatient Managementepartment. VAD patients should be transported to hospitals
hat have device expertise and are adept with their emergency
eeds. However, this is not always feasible.
First responders need to be aware of the necessary steps to
ollow when a VAD stops operating due to a mechanical or
ower failure including changing batteries, connecting to an
lternative means of alternating current (AC) power, and
he techniques for hand pumping a pulsatile device (Fig. 4).
urrent Clinical Studies of VADsTable 4 Current Clinical Studies of VADs
Name of Trial Study Objectives
CentriMag Ventricular Assist
System in Treating
Failure-to-Wean From
Cardiopulmonary Bypass
Nonrandomized trial to determine the safety and
efficacy of the Levitronix CentriMag
ventricular assist system in hemodynamically
unstable patients with cardiac dysfunction
who cannot be weaned from cardiopulmonary
bypass for up to 30 days
EXCOR Pediatric Ventricular
Assist Device (VAD) as a
Bridge-to-Cardiac
Transplantation
Prospective multicenter, historical control, single-
arm study to examine the safety and potential
benefit of the Berlin Heart EXCOR Pediatric
VAD as a bridge to cardiac transplantation in
children
HARPS (Harefield Recovery
Protocol Study for
Patients With Refractory
Chronic Heart Failure)
Nonrandomized, open-label, multicenter trial to
assess the percentage of HeartMate XVE
patients who, when treated with clenbuterol
in conjunction with conventional oral heart
failure medications, recover adequate cardiac
function to be removed from VAD support and
not require heart transplantation
Evaluation of the HeartWare
Left Ventricular Assist
Device for the Treatment
of Advanced Heart Failure
Open-label, nonrandomized study to establish
the safety and effectiveness of the HeartWare
LVAD system in refractory heart failure
patients listed for cardiac transplantation
Jarvik 2000 Heart as a
Bridge to Cardiac
Transplantation—
Pivotal Trial
Phase II and III study to ascertain the safety and
effectiveness of the Jarvik 2000 Heart as a
bridge to heart transplantation in end-stage
heart failure patients who are approved
transplantation candidates
Evaluation of Myocardial
Improvement in Patients
Supported by Ventricular
Assist Device Under
Optimal Pharmacological
Therapy
Randomized, single-blind trial designed to
assess the recovery of myocardial function in
VAD bridge to transplantation patients treated
with either high- or standard-dose
pharmacologic therapy
Thoratec HeartMate II Left
Ventricular Assist System
(LVAS) for Destination
Therapy
Prospective, multicenter, noninferiority trial
evaluating the efficacy and safety of the
HeartMate II in ineligible transplantation
patients with NYHA functional class III or IV
heart failure. Patients will be randomized in a
2-to-1 basis to the HeartMate II and the
HeartMate XVE
VentrAssist LVAD for the
Treatment of Advanced
Heart Failure
Multicenter, prospective, randomized, controlled
clinical trial to explore the use of the
VentrAssist LVAD in patients with chronic
stage D heart failure who are ineligible for a
heart transplantation
VentrAssist LVAD as a
Bridge to Cardiac
Transplantation—
Feasibility Trial
Nonrandomized, historical control phase II and III
clinical trials of the VentrAssist LVAD, a
centrifugal flow pump, to determine the
safety and feasibility in patients who require
an LVAD as a bridge to cardiac
transplantation
his table lists current ongoing trials of VADs. Final results of these clinical investigations have not
et been published.
NYHA  New York Heart Association; other abbreviations as in Table 3.hey should be taught to anticipate that patients with axial aow technology are usually pulseless and that no backup
upport is available.
ardiopulmonary resuscitation and cardioversion. Car-
ioversion or defibrillation is possible with all technolo-
ies, as is intubation. When external defibrillation is
equired, the VAD system controller should be discon-
ected before delivering the shock to avoid electronic
isruption. Health care workers should be instructed not
o treat a cardiac arrhythmia or perform cardiopulmonary
esuscitation in an asymptomatic individual if the device
s functioning properly. Chest compression may lead to
islodging of the tubing or damage to the device itself.
ost importantly, emergency personnel should always
isten to the patient and keep his or her companions close
y for they have been educated on the therapies that can
r cannot be delivered.
lectrical utilities. Electric utility companies are notified
o place VAD patients on a list for priority power
estoration in the event of a power outage as well as to
rrange for portable generators. Power companies are
sked to prevent planned outages at the patient’s home
nd be advised not to shut off electricity for nonpayment
f electric bills. The local community police and fire
epartments should be aware of the VAD patients in
heir district and in extreme circumstances may be alerted
o provide emergency backup power. Before leaving the
ospital, the electrical supply at a patient’s residence must
ndergo a safety check, with proper grounding provided
or battery rechargers.
roposed Medical Management and Structuralnd Functional Targets* for VAD ExplantationTable 5 Proposed M dical Management and Structuraland Functional Targets* for VAD Explantation
Pharmacologic Management
Stage 1: After discontinuation of inotropic therapy
Lisinopril 40 mg daily
Carvedilol 50 mg twice daily
Spironolactone 25 mg daily
Losartan 100 mg daily
Stage 2: Normal left ventricular end-diastolic diameter for a minimum
of 2 weeks
Carvedilol discontinued and bisoprolol initiated
Clenbuterol 40 g twice daily (titrated to 700 g 3 times daily)
Assessment Modality Target
Echocardiography
Left ventricular end-diastolic diameter, mm 60
Left ventricular end-systolic diameter, mm 50
Left ventricular ejection fraction, % 65
Cardiac catheterization
Pulmonary capillary wedge pressure, mm Hg 12
Resting cardiac index, l/min/m2 2.8
Cardiopulmonary exercise test
Peak V˙O2, ml/kg/min 16
V˙E/V˙CO2 slope 34
odified from Birks et al. (22).*All measurements must be made when the LVAD has been off for
5 minutes.
V˙O2  oxygen consumption; V˙E/V˙CO2  minute ventilation to carbon dioxide production; other
bbreviations as in Table 3.
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ongitudinal outpatient management of VAD patients is
rucial for a successful outcome. This care is typically led by
he cardiology service along with a team of members
ncluding a nurse or VAD coordinator, primary care physi-
ian, surgeon, and specialists. All coexisting noncardiac
edical conditions, such as diabetes, must be aggressively
anaged.
lood pressure. Blood pressure needs to be carefully
easured because systemic hypertension has been seen in
oth ischemic and nonischemic cardiomyopathy patients
ith pulsatile VADs. Obtaining systolic pressure by
adial artery palpation is preferred over brachial artery
uscultation for conventional pulsatile technology be-
ause the device itself can transmit sounds that can be
onfused with Korotkoff sounds. With axial flow pumps,
o audible aortic valve closure sound occurs because there
s no or minimal pulse pressure. The Korotkoff sound
eard upon auscultation is actually the mean blood
ressure. When defining the blood pressure, it is recom-
ended that a Doppler flow probe be used to help define
he blood pressure. If present, hypertension should be
reated aggressively to help reduce the incidence of
Figure 4 HeartMate XVE Hand Pump
In cases of an emergency such as a failure of the primary and backup drivers,
a hand pump should be used immediately to restore flow to a pulsatile ventric-
ular assist device (VAD). To use a hand pump properly, the system controller
must be disconnected from the power source. Next, the hand pump bulb
should be connected to the end of the driveline vent filter and the system
primed by holding down the purge valve on the pump and collapsing the bulb.
The hand pump delivers pulses of air to the pusher plate, generating a stroke
volume. One hand pump is needed for each VAD. The pump should be
squeezed approximately 60 to 90 times per minute to empty and fill the blood
chambers. Figure illustration by Rob Flewell.eurologic events, end-organ damage, or VAD dysfunc- tion. In patients with a continuous flow pump, we aim for
mean blood pressure between 70 and 90 mm Hg. This
ometimes will necessitate the use of multiple agents.
nticoagulation and antiplatelet therapy. Anticoagula-
ion or antiplatelet therapy is a central component of
utpatient management because thromboembolism is
ssociated with all devices. International normalized
atios of 1.5 to 2.5 are currently targeted for pneumati-
ally driven pulsatile devices. In patients with a contin-
ous flow pump, some VAD centers are now recom-
ending a lower international normalized ratio of 1.7 to
.3. If an individual experiences a neurologic event, a
igher international normalized ratio may be targeted.
linicians must carefully weigh the chance of a throm-
oembolic event against the vulnerability of a bleed
ssociated with excessive anticoagulation. Such patients
hould be monitored closely to minimize the risk of a
astrointestinal or intracranial bleed or severe epistaxis.
djustments to the warfarin regimen may be directed by
he community physician in conjunction with a patient’s
pecific needs and the established practicing patterns of
he implant center.
Most device manufacturers also recommend antiplatelet
herapy with aspirin because patients always remain at risk
f stasis thrombus, hemolysis, and shear-induced platelet
ysfunction. Additionally, studies on platelet function have
hown that after VAD insertion, an up-regulation of plate-
et activation markers and function occurs (35,36). Due to
he reported risk of aspirin resistance, which may occur in as
any as 40% of individuals, all VAD patients should have
heir platelet responsiveness to aspirin determined (37). To
elp individualize therapies, studies have assessed the use of
hromboelastographic monitoring to guide therapy and
ecrease the risk of thromboembolic events and prevent
leeding complications (38). Additionally, these drug regi-
ens can be modified based on the patient’s history (e.g.,
rug-eluting stent).
Data from newer and next-generation devices along with
ndividual institutional experiences demonstrate lower rates
f thromboembolic and cerebrovascular events, suggesting
hat less stringent anticoagulation requirements may be
ecessary in selected populations. The HeartMate XVE
AD can be managed with antiplatelet therapy alone
ecause of its unique surface that allows for neointima
ormation and the presence of bioprosthetic unidirectional
alves. Warfarin may be added in patients with a HeartMate
VE VAD if they have another indication for anticoagu-
ation (e.g., atrial fibrillation or venous or systemic throm-
oembolism).
leeding. Bleeding after VAD insertion may be related to
ystemic anticoagulation or potentially acquired von Wille-
rand disease (39). Additionally, higher rates of gastroin-
estinal bleeds have been reported in patients with nonpul-
atile VADs (40). The lower pulse pressure of nonpulsatile
evices may lead to hypoperfusion of the bowel wall leading
o vascular dilation and angiodysplasia (41). If significant
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October 27, 2009:1647–59 Ventricular Assist Devices: Outpatient Managementleeding occurs, anticoagulation can often be withheld for
eeks to months safely, and patients must be immediately
tabilized. Future decisions about reinstitution of anticoag-
lation should be made by the primary VAD team. Patients
ith nonthreatening gastrointestinal bleeds (e.g., guiac-
ositive stools, slight decrease in hematocrit) can safely
ndergo upper and lower endoscopy by local care providers.
f localization of the bleed cannot be determined, further
valuation at the VAD center may include small bowel
apsule endoscopy to assess for arteriovenous malforma-
ions. At such time, close observation must be maintained
ue to the potential risk of interference between the
lectromagnetic devices (42).
ardiac pacemakers and implantable cardioverter-
efibrillators (ICDs). ICD management may present
hallenges. There have been reports from clinical trials that,
ue to electromagnetic disturbances, a minority of ICDs
nd pacemakers cannot establish telemetry and be repro-
rammed. However, the majority of ICDs do not interact
ith normal VAD operation and vice versa (43). If an
ncompatible device is present, an alternative device should
e inserted in the majority of patients requiring ICD
rotection.
entricular arrhythmias. Ventricular arrhythmias are not
ncommon in VAD patients, especially in those with an
nderlying ischemic cardiomyopathy (44). Often, ventricu-
ar tachycardia or fibrillation may cause little change in
AD flow, with relative preservation of cardiac output and
onsciousness (45). These arrhythmias, however, are asso-
iated with a more malignant course and an increased
ortality risk and suggest that the use of ICDs in this
etting is appropriate (46,47). Unique to the axial flow
umps, excessive ventricular unloading leading to suction of
he left ventricular wall or septum into the draining cannula
an induce ventricular tachycardia. This is the most com-
on cause of ventricular tachycardia in axial pumps and
erminates after clearance of suction (48). If suspected, an
chocardiogram should be performed.
ong-Term Complications
ince the publication of the landmark REMATCH (Ran-
omized Evaluation of Mechanical Assistance for the
reatment of Congestive Heart Failure) trial in 2001 (7),
efinement in devices and the adoption of best practice
anagement techniques have improved the short- and
ong-term care of patients (49,50). Perioperative complica-
ions include hemorrhage, right ventricular failure, sepsis,
ir embolism, and kinking of conduits. The most common
ate complications are mechanical device failure, neurologic
vents, and infection (7,51,52).
echanical failure. Device malfunction is an important
ause of morbidity and mortality in patients living with
ADs, especially with the prolonged support required for
oth bridge to transplantation and destination therapy. In
he REMATCH trial, 35% of patients experienced compo- rent failure within 24 months of implantation (7). A
ontemporary review of 109 pulsatile VADs implanted at a
ingle institution found that the probability of device failure
as 6%, 12%, 27%, and 64% at 6 months, 1 year, 18
onths, and 2 years, respectively (53). Mechanical durabil-
ty of continuous flow pumps seems to be markedly im-
roved. In a bridge to transplantation study, only 5 of 133
4%) patients with a HeartMate II VAD developed either
evice thrombosis or a complication from surgical implan-
ation necessitating device replacement. Such devices are
onstructed from fewer components subject to mechanical
ailure (11).
Complications can arise in any component from the
ortable drive/system controller that controls and powers
he device to the inflow and outflow cannulae, valves,
atteries, and the VAD itself. All devices have system
ontrollers and monitors to provide visual and auditory
larms during malfunction. These alarms must be used in
onjunction with clinical, laboratory, and imaging data to
iagnose suspected device malfunction. For troubleshoot-
ng, systematic catheter-, angiography-, fluoroscopy-, and
chocardiography-based protocols have been developed to
elp diagnose common malfunctions (54–57). If necessary,
epair of a dysfunctional VAD or removal and replacement
ith a new VAD may be performed.
eurologic events. Implanted mechanical devices are
usceptible to thromboembolic events due to their unique
roperties. The foreign surfaces of VADs can activate the
mmune system, platelets, and the coagulation cascade. In
ddition, the blood-contact surfaces of VADs along with
urbulent blood flow increase the risk of shear stress on
lood and thrombi formation (58). Other risk factors for
he development of neurologic events include the un-
asking or inadequate treatment of hypertension, older
ge, higher VAD flow and index, and inadequate
nticoagulation.
Neurologic complications from VAD therapy include
erebrovascular accidents and transient ischemic attacks,
ith an incidence ranging from 0.009 to 5.73 events per
atient-year (58,59). The prevalence of neurologic events
ith destination therapy has ranged from 44% in the
EMATCH trial (HeartMate XVE) to 57% in the
uropean LionHeart Clinical Utility Baseline Study,
ith 21% and 43%, respectively, resulting in permanent
eurologic injury (58,60). Intracranial hemorrhage, syn-
ope, seizure, brain abscesses, and encephalopathy have
ll been reported. These data are mostly from the
ridge-to-transplantation experience and may not apply
o destination therapy patients who are generally older
nd have more comorbidities and longer implantation
eriods (60).
Not all devices have the same neurologic event rate.
esign modifications incorporated in the newer generation
f VADs, including the use of novel biologic materials,
extured coatings, and a single moving part, are believed to
educe the risk of thrombus formation. Promising data from
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Ventricular Assist Devices: Outpatient Management October 27, 2009:1647–59he recently completed HeartMate II trial demonstrated
educed adverse events per patient year with respect to
troke (0.19 vs. 0.44) and nonstroke (0.26 vs. 0.67) neuro-
ogic events compared with a pulsatile flow pump (11).
ppropriate device selection, prevention of infection that
an activate platelets, blood pressure control, and meticulous
egulation of anticoagulation are all critical for the preven-
ion of cerebrovascular accidents after VAD implantation
61,62).
nfection. INFECTIONS ASSOCIATED WITH VADS. VAD
nfections can occur at any time, but occur most frequently
etween 2 weeks and 2 months after implantation (63).
evice-related infections are caused predominantly by the
ram-positive organisms Staphylococcus epidermidis and
taphylococcus aureus followed by enterococci (64–66).
ther commonly implicated organisms include Gram-
egative bacilli such as Pseudomonas aeruginosa, Enterobacter,
nd Klebsiella species, along with fungi (65,67). Frequent
se of broad-spectrum antibiotics, particularly during the
ndex hospitalization, is believed to increase susceptibility
or fungal infections, which are associated with the highest
Figure 5 Suggested Algorithm to Assess a Patient With a VAD
Guidelines for the evaluation of an infectious process in a patient with a ventricula
CBC  complete blood count; MRSA  methicillin-resistant Staphylococcus aureuisk of death (67,68). wOCATION OF INFECTIONS. The entire VAD is susceptible
o infection including the surgical site, device pocket,
riveline, valves, and conduits. The most common site of
nfection is the percutaneous driveline, which can often be
anaged successfully with wound care and antibiotics (69).
owever, a driveline infection can spread to other compo-
ents of the VAD resulting in bacteremia, sepsis, and
ndocarditis (Fig. 5) (70). Sepsis in patients with mechan-
cal assist devices has been reported to be the leading cause
f death and can result in cerebral emboli and multiorgan
ailure (65,67). Other infections, including mediastinitis
nd peritonitis, have also been reported.
TEPS FOR THE PATIENT AND CAREGIVERS TO REDUCE
ISK OF INFECTIONS. Many strategies, primarily based on
linical experience, have been adopted to try to minimize
evice-related and wound infections. Proper care of the
riveline exit site must be maintained. Every day patients or
heir caregivers must strictly adhere to aseptic technique
e.g., sterile gloves, mask) when caring for the percutaneous
xit site. The site should be gently cleaned with a mild
ntimicrobial soap and rinsed with sterile normal saline after
Fever or Leukocytosis
st device (VAD).
 transesophageal echocardiography.With
r assi
s; TEEhich a dry sterile dressing should be applied. At all times,
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October 27, 2009:1647–59 Ventricular Assist Devices: Outpatient Managementhe driveline must be secured to minimize the risk of
rauma; immobilization can be performed with an abdom-
nal binder, additional gauze, tape, or a stoma-adhesive
evice (71,72). Injury to the delicate exit site through either
shearing traction or torsion injury is the initiating mech-
nism for most late driveline infections (73). Patients should
e educated to monitor for any changes to the exit site and
o notify their health care team immediately if there are
igns of infection.
NFECTION-ASSOCIATED DESIGN MODIFICATIONS. Since
he introduction of VADs, many modifications to device
esign have been made to further decrease the risk of
nfection. These include the use of use of larger single-lead
rivelines and drivelines coated with chlorhexidine and
ilver sulfadiazine to reduce colonization and augment
nitial tissue ingrowth (67,73). Studies of rotary blood
umps with their reduced surface area for colonization and
maller surgical pump pocket suggest that they are less
rone to infection (74,75). Future research to reduce device-
elated infections will focus on the influence of the pump
urfaces on the native immune system to develop more
iocompatible materials (76–78). It is hoped that one day,
completely implantable device without a driveline will be
nserted and will dramatically reduce device-related
nfections.
OL
espite potential complications, VADs significantly im-
rove QOL in patients with end-stage heart failure. When
urveyed about lifestyle changes, VAD patients highlight
he ability to drive, exercise, travel, return to work or school,
nd engage in hobbies and sexual activity as major contrib-
tors to improved QOL (79,80). In the REMATCH study,
cores on the physical-function and emotional-role sub-
cales of the Short Form Health Survey and the New York
eart Association functional class were all better with the
eartMate XVE VAD at 1 year (7). In addition, the
innesota Living With Heart Failure Questionnaire score
as improved with destination VAD compared with opti-
al medical management (34 points vs. 13 points, respec-
ively) (7). This magnitude of QOL improvement surpasses
hat achieved with adjunctive pharmacologic or cardiac
esynchronization therapy in patients with advanced heart
ailure (81,82).
More recently, in patients awaiting heart transplantation,
he HeartMate II continuous flow device improved QOL at
months on multiple validated indexes (27 on the
innesota Living With Heart Failure Questionnaire and
22 on the Kansas City Cardiomyopathy Questionnaire)
11). The impact of different devices on QOL has not been
ompared directly in clinical trials to date. In theory, QOL
ay be even greater with rotary devices because of their
maller size and quieter operation compared with pulsa-
ile VADs. Given the rapid evolution of mechanical
irculatory support, QOL outcome measures have be-ome an integral part of all clinical trials and registries
nvolving VADs (83).
onclusions
s VAD technology progresses, collaboration of multidis-
iplinary teams composed of engineers, scientists, physi-
ians, and nurses will continue to refine the technology and
mprove patient care and outcomes. Advances in device
esign will allow easier implantation and create smaller,
ore efficient, durable, and reliable units. The National
eart, Lung and Blood Institute in collaboration with the
enters for Medicare & Medicaid Services and the U.S.
ood and Drug Administration has established a national
egistry called INTERMACS (Interagency Registry for
echanically Assisted Circulatory Support) (83). Most
AD implantation hospitals are members, and patients who
eceive a U.S. Food and Drug Administration–approved
echanical circulatory support device are entered and fol-
owed prospectively. This registry will be used to help refine
election criteria for VAD therapy, inform best practice
uidelines, and allow clinicians to provide patients more
nformation about device comfort, QOL, and survival after
AD implantation. In light of the growing population of
atients with advanced heart disease, the shortage of suit-
ble donors, and evolving technology, mechanical circulatory
upport devices will play an ever-increasing role in the care of
atients with end-stage heart failure.
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